{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:53Z","timestamp":1786982873363,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf - Case Rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40800-018-0087-y","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T06:18:18Z","timestamp":1526019498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report"],"prefix":"10.1007","volume":"5","author":[{"given":"Lara","family":"Farhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmeen","family":"Dara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Duberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliva","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"issue":"18","key":"87_CR1","first-page":"2","volume":"22","author":"M Etemadifar","year":"2017","unstructured":"Etemadifar M, Salari M, Mirosayyeb O, Serati M, Nikkah R, Askari M, Fayyazi E. Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci. 2017;22(18):2.","journal-title":"J Res Med Sci."},{"key":"87_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/B978-0-12-802395-2.00019-5","volume":"145","author":"R Hoftberger","year":"2017","unstructured":"Hoftberger R, Lassmann H. Inflammatory demyelinating diseases of the central nervous system. Handb Clin Neurol. 2017;145:263\u201383.","journal-title":"Handb Clin Neurol."},{"key":"87_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jns.2016.11.016","volume":"372","author":"ME Evangelopoulos","year":"2017","unstructured":"Evangelopoulos ME, Andreadou E, Koutsis G, Koutoulidis V, Anagnostouli M, Katsika P, Evangelopuols DS, Evdokimidis I, Kilidireas C. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. J Neurol Sci. 2017;372:92\u20136.","journal-title":"J Neurol Sci."},{"key":"87_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.nrl.2014.09.001","volume":"30","author":"MJ Fern\u00e1ndez-Meg\u00eda","year":"2015","unstructured":"Fern\u00e1ndez-Meg\u00eda MJ, Casanova-Estruch B, P\u00e9rez-Miralles F, Ruiz-Ramos J, Alcal\u00e1-Vicente C, Poveda-Andr\u00e9s JL. Clinical evaluation of rituximab treatment for neuromyelitis optica. Neurologia. 2015;30:461\u20134.","journal-title":"Neurologia"},{"issue":"15","key":"87_CR5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T. Long-term follow up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310\u20135.","journal-title":"Neurology"},{"issue":"10","key":"87_CR6","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","volume":"262","author":"H Z\u00e9phir","year":"2015","unstructured":"Z\u00e9phir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R. Brassat. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015;262(10):2329\u201335.","journal-title":"J Neurol."},{"issue":"9","key":"87_CR7","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/ppul.20864","volume":"44","author":"M Bitzan","year":"2009","unstructured":"Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol. 2009;44(9):922\u201334.","journal-title":"Pediatr Pulmonol."},{"key":"87_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","volume":"13","author":"C Casulo","year":"2013","unstructured":"Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13:106\u201311.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"87_CR9","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/10428190500473113","volume":"47","author":"C Cattaneo","year":"2006","unstructured":"Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, Ungari M, Ruggeri G, Rossi G. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma. 2006;47:1013\u20137.","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"87_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1365-2141.2009.07715.x","volume":"146","author":"N Cooper","year":"2009","unstructured":"Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol. 2009;146(1):120\u20132.","journal-title":"Br J Haematol."},{"issue":"12","key":"87_CR11","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896\u2013908.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"87_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","volume":"149","author":"N Cooper","year":"2010","unstructured":"Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010;149(1):3\u201313.","journal-title":"Br J Haematol."},{"issue":"2","key":"87_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther."},{"key":"87_CR14","first-page":"6","volume":"147","author":"PJ Cole","year":"1986","unstructured":"Cole PJ. Inflammation: a two-edged sword\u2014the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6\u201315.","journal-title":"Eur J Respir Dis Suppl"},{"key":"87_CR15","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thx.2010.136119","volume":"65","author":"MC Pasteur","year":"2010","unstructured":"Pasteur MC, Bilton D, Hill AT. British thoracic society bronchiectasis non-CF guideline group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65:i1\u201358.","journal-title":"Thorax"}],"container-title":["Drug Safety - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40800-018-0087-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40800-018-0087-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40800-018-0087-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T19:21:33Z","timestamp":1557516093000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40800-018-0087-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["87"],"URL":"https:\/\/doi.org\/10.1007\/s40800-018-0087-y","relation":{},"ISSN":["2199-1162","2198-977X"],"issn-type":[{"value":"2199-1162","type":"print"},{"value":"2198-977X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]},"assertion":[{"value":"11 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No financial support was received for the conduct of this study or preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and the accompanying images. A copy of the written consent may be requested for review from the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Lara Farhat, Jasmeen Dara, Susan Duberstein, and Aliva De have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"22"}}